Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $101.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target boosted by B. Riley from $61.00 to $101.00 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on ARWR. HC Wainwright upped their price target on Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank Of Canada raised their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Chardan Capital upped their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. The Goldman Sachs Group lifted their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $67.05 on Thursday. The firm has a 50 day moving average of $62.41 and a 200-day moving average of $40.11. The stock has a market capitalization of $9.11 billion, a PE ratio of -838.02 and a beta of 1.21. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $76.76. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43.

Insider Buying and Selling

In other news, CEO Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, December 15th. The stock was sold at an average price of $68.85, for a total value of $8,950,500.00. Following the completion of the transaction, the chief executive officer directly owned 3,971,255 shares in the company, valued at approximately $273,420,906.75. The trade was a 3.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 16,250 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $61.03, for a total value of $991,737.50. Following the sale, the director directly owned 115,240 shares in the company, valued at $7,033,097.20. This trade represents a 12.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 510,836 shares of company stock valued at $33,603,060 over the last three months. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently modified their holdings of the company. iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $29,000. Virtus Advisers LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth $34,000. Salomon & Ludwin LLC bought a new stake in Arrowhead Pharmaceuticals during the third quarter valued at $34,000. Nisa Investment Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,308 shares during the period. Finally, Federated Hermes Inc. bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter worth about $52,000. 62.61% of the stock is currently owned by institutional investors.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS estimates, reiterated a “Buy” rating and a $100 price target — the firm says improving forecasts and program progress support upside. HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals
• Positive Sentiment: B. Riley bumped its price target to $101 (from $61) and kept a “Buy” stance, implying significant upside from recent levels and signaling continued analyst conviction after Arrowhead’s program updates. B. Riley Raises ARWR Price Target to $101
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline ahead of Phase III hypertriglyceridemia data and has increased its target (reported lift to $110), underscoring the potential for a clinical readout to re‑rate the stock if data are positive. Piper Sandler Highlights Arrowhead Pipeline
• Neutral Sentiment: Broader coverage pieces (InsiderMonkey/TheFly) recap the analyst upgrades and pipeline milestones — useful for context but largely reiterative of the broker notes above. InsiderMonkey: Piper Sandler Highlights Arrowhead
• Negative Sentiment: Despite the upgrades, shares are down today amid lower‑than‑average volume — likely profit‑taking following the recent run and continued investor caution given persistent GAAP losses and upcoming binary clinical readouts (which carry upside but also clinical risk).

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.